SCHEMBL3660413

SCHEMBL3660413

CCOC(=O)N1CCn2c(nc(-c3ccncc3)cc2=O)C(NC(=O)c2cc(Cl)ccc2OC)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 1/20 0.41
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
DRD2 P14416 1/20 0.40
CDC7 O00311 1/20 0.38
ROCK2 O75116 1/20 0.38
PIM1 P11309 1/20 0.38
GSK3B P49841 1/20 0.38
HIPK2 Q9H2X6 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
P2RY12 Q9H244 2/20 0.38
MAPT P10636 5/20 0.38
LMNA P02545 4/20 0.38
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3667749 0.87 HPGD (0.40) HCRTR1HCRTR2CDC7ROCK2PIM1
SCHEMBL3664429 0.87 GSK3B (0.43) HCRTR1HCRTR2CDC7ROCK2PIM1
SCHEMBL2066338 0.86 KCNMA1 (0.46) KCNMA1DRD2MAPTLMNAALDH1A1
SCHEMBL3664954 0.85 GSK3B (0.37) HCRTR1HCRTR2CDC7ROCK2PIM1
SCHEMBL3662447 0.85 GSK3B (0.45) HCRTR1HCRTR2GSK3B
SCHEMBL3668510 0.84 DRD4 (0.45) KCNMA1DRD2MAPTLMNAPOLB
SCHEMBL3657923 0.82 NOS1 (0.44) GSK3BP2RY12MAPTALDH1A1SMN1; SMN2
SCHEMBL3663942 0.82 KCNMA1 (0.44) KCNMA1DRD2GSK3BMAPTALDH1A1
SCHEMBL3401265 0.82 KCNMA1 (0.44) KCNMA1DRD2MAPTALDH1A1POLB
SCHEMBL3663708 0.81 P2RY12 (0.44) CDC7ROCK2PIM1GSK3BHIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2238141-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA Sanofi-Aventis (FR) 2010-10-13 EP claimed
WO-2009095789-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA SANOFI-AVENTIS (FR) 2009-08-06 WO claimed
EP-2238141-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA Sanofi-Aventis (FR) 2010-10-13 EP disclosed
WO-2009095789-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA SANOFI-AVENTIS (FR) 2009-08-06 WO disclosed